The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum
Open accessAbstract
Proteolytic degradation of peptide-based drugs is often considered as major weakness limiting systemic therapeutic applications. Therefore, huge efforts are typically devoted to stabilize sequences against proteases present in serum or plasma, obtained as supernatants after complete blood coagulation or centrifugation of blood supplemented with anticoagulants, respectively. Plasma and serum are reproducibly obtained from animals and humans allowing consistent for clinical analyses and research applications. However, the spectrum of active or activated proteases appears to vary depending on the activation of proteases and cofactors during coagulation (serum) or inhibition of such enzymes by anticoagulants (plasma), such as EDTA (metallo- and Ca2+-dependent proteases) and heparin (e.g. thrombin, factor Xa). Here, we studied the presumed effects on peptide degradation by taking blood via cardiac puncture of CD-1 mice using a syringe containing a peptide solution. Due to absence of coagulation activators (e.g. glass surfaces and damaged cells), visible blood clotting was prevented allowing to study peptide degradation for one hour. The remaining peptide was quantified and the degradation products were identified using mass spectrometry. When the degradation rates (half-life times) were compared to serum derived freshly from the same animal and commercial serum and plasma samples, peptides of three different families showed indeed considerably different stabilities. Generally, peptides were faster degraded in serum than in plasma, but surprisingly all peptides were more stable in fresh blood and the order of degradation rates among the peptides varied among the six different incubation experiments. This indicates, that proteolytic degradation of peptide-based therapeutics may often be misleading stimulating efforts to stabilize peptides at degradation sites relevant only in vitro, i.e., for serum or plasma stability assays, but of lower importance in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, D. B., & Johnson, K. S. (1988) · Gene · doi:10.1016/0378-1119(88)90005-4 · Cited by 5,892
Overview of the coagulation system
Palta, S., Saroa, R., & Palta, A. (2014) · Indian Journal of Anaesthesia · doi:10.4103/0019-5049.144643 · Cited by 901
Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors
Rawlings, N. D., Barrett, A. J., & Finn, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1118 · Cited by 687
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Evolution of Proteolytic Enzymes
Neurath, H. (1984) · Science · doi:10.1126/science.6369538 · Cited by 644
Gentilucci, L., De Marco, R., & Cerisoli, L. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793292555 · Cited by 586
Differences between Human Plasma and Serum Metabolite Profiles
Yu, Z., Kastenmüller, G., He, Y., Belcredi, P., Möller, G., Prehn, C., Mendes, J., Wahl, S., Roemisch-Margl, W., Ceglarek, U., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021230 · Cited by 492
Apidaecins: antibacterial peptides from honeybees.
Casteels, P., Ampe, C., Jacobs, F., Vaeck, M., & Tempst, P. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb08368.x · Cited by 469
The emergence of peptides in the pharmaceutical business: From exploration to exploitation
Uhlig, T., Kyprianou, T., Martinelli, F. G., Oppici, C. A., Heiligers, D., Hills, D., Calvo, X. R., & Verhaert, P. (2014) · EuPA Open Proteomics · doi:10.1016/j.euprot.2014.05.003 · Cited by 456
Blood Coagulation: Hemostasis and Thrombin Regulation
Tanaka, K. A., Key, N. S., & Levy, J. H. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bcc9c · Cited by 342
Cited by
Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity
Sæbø, I., Bjørås, M., Franzyk, H., Helgesen, E., & Booth, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032914 · Cited by 461
Meade, E., Slattery, M. A., & Garvey, M. (2020) · Antibiotics · doi:10.3390/antibiotics9010032 · Cited by 320
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
Dermawan, D., & Alotaiq, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-93683-1 · Cited by 19
Zeng, W., Horrocks, K. J., Tan, A. C. L., Wong, C. Y., Chua, B. Y., & Jackson, D. C. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.10.055 · Cited by 4
Metadata
- Authors
- Böttger, R., Hoffmann, R., & Knappe, D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-06-02
- Volume
- 12
- Issue
- 6
- Pages
- e0178943
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2620755219
- Cited by
- 307
- References
- 31
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. https://app.cochat.ai/papers/10.1371/journal.pone.0178943
- The paper
- Böttger, R., Hoffmann, R., & Knappe, D. (2017). Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLOS ONE. https://doi.org/10.1371/journal.pone.0178943
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.